GBR 1372
Alternative Names: GBR1372Latest Information Update: 28 Mar 2023
At a glance
- Originator Glenmark Pharmaceuticals Ltd
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD3 antigen modulators; Cytotoxic T lymphocyte modulators; Epidermal growth factor receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Colorectal cancer; Squamous cell cancer
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for preclinical development in Colorectal-cancer in India (Parenteral)
- 28 Mar 2023 No recent reports of development identified for preclinical development in Squamous-cell-cancer in India (Parenteral)
- 28 Nov 2020 No recent reports of development identified for preclinical development in Cancer in India (Parenteral)